Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. People with schizophrenia may seem like they have lost touch with reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be very disabling. According to the National Institute of Mental Health, about 1% of the population will have schizophrenia during their lifetime.
Schizophrenia often develops in late adolescence or early adulthood, and so it can seriously disrupt a person’s education or career trajectory when it first appears. Some key signs and symptoms of schizophrenia include hallucinations, delusions, disorganized thinking or speech, grossly disorganized or abnormal motor behavior, and negative symptoms like a lack of pleasure in everyday life, lack of emotional response, or inability to start and follow through with activities. These symptoms can range from mild to severe.
There is no single, known cause of schizophrenia. Research suggests that a combination of environmental, psychological, and biological factors likely contribute to causing schizophrenia. Genetics seem to play a significant role, with studies showing that people who have a first-degree relative (parent, sibling, or child) with schizophrenia have a 10% risk of developing the disorder compared to around 1% for the general population. Some potential environmental factors include fetal damage from viral infection during pregnancy, complications during birth or delivery, malnutrition during pregnancy, and drug or alcohol abuse during adolescence or early adulthood. None of these factors alone are known to cause schizophrenia.
Currently, schizophrenia has no cure, but it is a treatable condition. Many people with schizophrenia can experience good control of their symptoms and maintain a good quality of life with consistent treatment. The most common treatment model is called “coping skills training” which helps people recognize signs that their symptoms are worsening and utilize strategies to prevent relapse, and may draw from cognitive behavioral therapy techniques. Antipsychotic medications are also a core treatment for controlling symptoms like hallucinations and delusions. About one-third of people with schizophrenia do not respond adequately to available antipsychotic drugs.
Neuroscientists continue research to better understand the complex biological underpinnings of schizophrenia to develop improved treatments and interventions. Current theories suggest that schizophrenia may result from a combination of abnormal dopamine activity and glutamate dysfunction in brain circuits involved in emotion, thought, and behavior. Structural and functional brain imaging studies have found differences in brain structure and activity, especially in prefrontal regions, of people with schizophrenia compared to healthy controls.
As our understanding of schizophrenia’s underlying biology advances, researchers hope to discover more targeted drug treatments. Promising areas of investigation include development of “dopamine normalizers” and glutamate modulators, as well as drugs aimed at regulating neuroplasticity and neuroprogression processes in schizophrenia. Scientists are also researching whether anti-inflammatory drugs or agents targeting abnormal immune responses in schizophrenia could have therapeutic benefit. Additionally, greater understanding of schizophrenia’s genetics may enable preemptive or preventative interventions for those at high genetic risk.
To aid this promising research, national and international collaborations collect large datasets on schizophrenia genetics, brain imaging, clinical symptoms and treatment outcomes. This “big data” approach enables researchers to identify subtle patterns and interactions related to the disorder which may not be apparent in smaller samples. For example, in 2019 researchers found 108 genetic sites associated with increased risk for developing schizophrenia by analyzing genome-wide association studies including around 800,000 individuals. Further investigation is also exploring whether particular genetic subtypes may underlie distinct symptom profiles or drug responses in schizophrenia.
Overall, ongoing multidisciplinary schizophrenia research holds hope for continued progress toward the goals of prevention, improved diagnosis, more individualized treatment strategies, and eventually stopping or even reversing the course of the illness. With continued advances in neuroscience, genetics, pharmacology, and clinical trials, we may someday understand schizophrenia well enough to reliably predict individual risks and offer personalized interventions to transform lives affected by this difficult condition. This integrated basic and translational research is critical to empowering those with schizophrenia to effectively manage their illness and pursue fulfilling lives.